严重创伤大量输血中血浆优先策略与生存改善独立相关
该观察性创伤质量改进项目(2013—2021)纳入到达4小时内接受至少5单位浓缩红细胞和1单位新鲜冰冻血浆的严重创伤患者,排除不可存活损伤模式和既存凝血病,共50,580例,其中13,818例采用血浆优先策略。倾向评分加权风险调整模型显示,红细胞优先策略与6小时死亡率(aOR 1.10;95%CI 1.02-1.18)、24小时死亡率(aOR 1.11;95%CI 1.05-1.18)和住院死亡率(aOR 1.06;95%CI 1.01-1.11)升高独立相关。严重颅脑损伤亚组和暴露敏感性分析中该关联未达统计学显著。作者认为血浆优先策略与改善生存独立相关,但效应量不大,需未来前瞻性或随机试验验证。
要点
- 严重创伤到达4小时内接受至少5单位浓缩红细胞和1单位新鲜冰冻血浆者,血浆优先策略与6小时死亡率降低独立相关(aOR 1.10;95%CI 1.02-1.18)。
- 血浆优先策略与24小时死亡率(aOR 1.11;95%CI 1.05-1.18)和住院死亡率(aOR 1.06;95%CI 1.01-1.11)降低独立相关。
- 未调整6小时、24小时和住院死亡率:红细胞优先分别为9.8%、15%、28%,血浆优先分别为8.9%、14%、27%。
- 严重颅脑损伤亚组中红细胞优先aOR 1.08(95%CI 0.95-1.23),暴露敏感性分析中aOR 1.02(95%CI 0.94-1.09),均未达统计学显著。
- 穿透性损伤机制与早期死亡显著相关;损伤类型未显示效应修饰。
适用人群与场景
- 创伤质量改进项目(2013—2021)中到达4小时内接受至少5单位浓缩红细胞和1单位新鲜冰冻血浆的严重创伤患者。
- 排除不可存活损伤模式和既存凝血病患者。
- 共50,580例纳入,其中13,818例采用血浆优先策略;平均年龄39岁,77%男性,60%钝性创伤,平均损伤严重度评分27。
- 严重颅脑损伤亚组分析纳入15,912例;暴露敏感性分析纳入27,217例。
研究设计与关键结果
- 研究类型:观察性创伤质量改进项目(2013—2021),采用倾向评分加权风险调整模型并按中心聚类。
- 主要终点6小时死亡率:红细胞优先策略aOR 1.10(95%CI 1.02-1.18),与死亡率升高独立相关。
- 次要终点24小时死亡率:红细胞优先策略aOR 1.11(95%CI 1.05-1.18);住院死亡率aOR 1.06(95%CI 1.01-1.11)。
- 未调整6小时、24小时和住院死亡率:红细胞优先分别为9.8%、15%、28%,血浆优先分别为8.9%、14%、27%。
- 严重颅脑损伤亚组:红细胞优先aOR 1.08(95%CI 0.95-1.23),未达统计学显著。
- 暴露敏感性分析:红细胞优先aOR 1.02(95%CI 0.94-1.09),未达统计学显著;血液制品分析结果与主分析一致。
- 损伤类型未见效应修饰;穿透性损伤机制与早期死亡显著相关。
证据类型、等级与局限
- 证据类型:观察性研究(创伤质量改进项目),证据等级为预后与流行病学Level III。
- 局限:作者指出效应量不大,需未来前瞻性或随机试验验证。
对床旁实践的改变
- 作者认为血浆优先策略与改善生存独立相关,效应量不大,需未来前瞻性或随机试验验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite evidence supporting high fresh frozen plasma (FFP)-to-packed red blood cell (PRBC) ratios, the optimal initial blood product in severe injury is unknown. We hypothesized that an FFP-first approach is associated with improved survival.
METHODS: An observational Trauma Quality Improvement Program (2013-2021), including patients who received at least 5 units of PRBCs and 1 unit of FFP within four hours of arrival, was performed. Nonsurvivable injury patterns and pre-existing coagulopathy were excluded. Treatment effects were estimated with propensity score-weighted risk adjustment models, clustering by center. The primary outcome was six-hour mortality. Secondary outcomes were 24-hour and in-hospital mortality. A subanalysis was performed on the severe head-injured, and a sensitivity analysis examined inclusion criteria and additional blood products (platelets and cryoprecipitate). Effect modification was assessed for injury type.
RESULTS: A total of 50,580 patients were included, with 13,818 in the FFP-first approach. Mean age was 39 years, with 77% males, 60% blunt trauma, and a mean Injury Severity Score of 27. Subanalysis included 15,912 patients, and the exposure sensitivity analysis included 27,217 patients. Unadjusted six-hour, 24-hour, and in-hospital mortality for the PRBC-first approach were 9.8%, 15%, and 28%, respectively, compared with 8.9%, 14%, and 27% for the FFP-first approach. A PRBC approach was independently associated with worse six-hour (adjusted Odds Ratio [aOR], 1.10; 95% CI, 1.02-1.18), 24-hour (1.11; 1.05-1.18), and in-hospital mortality (1.06; 1.01-1.11). The subgroup analysis of the PRBC aOR was 1.08 (95% CI, 0.95-1.23). In the exposure sensitivity analysis, the PRBC aOR was 1.02 (95% CI, 0.94-1.09). The blood products analysis was congruent with the main analysis. Effect modification was not present for injury type; however, penetrating mechanism was significantly associated with early death.
CONCLUSIONS: Although the effect was modest in magnitude, a FFP-first approach was independently associated with improved survival through hospital discharge. Future prospective or randomized trials are warranted. ( J Trauma Acute Care Surg . 2026;101: 610-618.).
LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.
参考来源
- Hynes AM, Westein RJ, Turner TJ, et al. Fresh frozen plasma-first approach is independently associated with improved survival in severely injured patients undergoing massive transfusion. J Trauma Acute Care Surg. 2026. PMID: 42275580. doi:10.1097/TA.0000000000005093
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。